» Authors » Matthew R Callstrom

Matthew R Callstrom

Explore the profile of Matthew R Callstrom including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 135
Citations 3113
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferrero A, Atwell T, Welch B, Kurup A, Callstrom M, Favazza C, et al.
J Vasc Interv Radiol . 2024 Dec; PMID: 39709123
This study aimed to perform temperature mapping during clinical ablations by leveraging the known relationship between computed tomography (CT) signal and temperature. First, the spectral CT signal was characterized as...
2.
Dhanasekaran M, Schmitz J, Castro M, Rajwani A, Lee R, Hamadi D, et al.
J Endocr Soc . 2024 Nov; 8(12):bvae175. PMID: 39502476
Background: Autonomously functioning thyroid nodules (AFTNs) constitute 5% to 7% of thyroid nodules and represent the second most common cause of hyperthyroidism following Graves' disease. Currently, radioactive iodine (RAI) and...
3.
Wang P, Kline T, Missert A, Cook C, Callstrom M, Chan A, et al.
J Imaging Inform Med . 2024 Apr; 37(5):2186-2194. PMID: 38587766
Automated segmentation tools often encounter accuracy and adaptability issues when applied to images of different pathology. The purpose of this study is to explore the feasibility of building a workflow...
4.
Gits H, Khosravi Flanigan M, Kapplinger J, Reisenauer J, Eiken P, Breen W, et al.
Chest . 2023 Dec; 165(5):1247-1259. PMID: 38103730
Background: Prolonged survival of patients with metastatic disease has furthered interest in metastasis-directed therapy (MDT). Research Question: There is a paucity of data comparing lung MDT modalities. Do outcomes among...
5.
Key B, Callstrom M, Filippiadis D
AJR Am J Roentgenol . 2023 May; 221(4):503-516. PMID: 37222277
Musculoskeletal interventional oncology is an emerging field that addresses the limitations of conventional therapies for bone and soft-tissue tumors. The field's growth has been driven by evolving treatment paradigms, expanding...
6.
Schmit G, Kurup A, Morris J, Kumar S, Schmitz J, Welch B, et al.
J Vasc Interv Radiol . 2023 Apr; 34(8):1303-1310. PMID: 37100197
Purpose: To evaluate the oncologic outcomes and adverse events associated with cryoablation of plasmacytomas. Materials And Methods: Retrospective review of an institutional percutaneous ablation database showed that 43 patients underwent...
7.
Potretzke T, Korfiatis P, Blezek D, Edwards M, Klug J, Cook C, et al.
Mayo Clin Proc . 2023 Mar; 98(5):689-700. PMID: 36931980
Objective: To evaluate the performance of an internally developed and previously validated artificial intelligence (AI) algorithm for magnetic resonance (MR)-derived total kidney volume (TKV) in autosomal dominant polycystic kidney disease...
8.
Navin P, Thompson S, Kurup A, Lee R, Callstrom M, Castro M, et al.
Radiographics . 2022 Oct; 42(6):1812-1828. PMID: 36190855
Thyroid nodule treatment has significantly evolved over recent years with attempts to individualize treatment on the basis of the cause of the nodule and patient performance status. The risks and...
9.
Reisenauer J, Eiken P, Callstrom M, Johnson G, Pierson K, Lechtenberg B, et al.
J Thorac Dis . 2022 May; 14(4):939-951. PMID: 35572874
Background: Percutaneous ablation is an alternative treatment for lung cancer in non-operable patients. This is a prospective clinical trial for percutaneous microwave ablation (pMWA) of biopsy-proven lung cancer to demonstrate...
10.
Klinkner D, Atwell T, Teles Abrao Trad A, Callstrom M, Qureshi M, Bendel Stenzel E, et al.
Fetal Diagn Ther . 2022 May; 49(5-6):250-255. PMID: 35490675
Introduction: Congenital pulmonary airway malformations (CPAMs) complicated by hydrops portend significant morbidity and mortality, with fetal survival estimates less than 10%. Case Presentation: We report successful use of ultrasound-guided radiofrequency...